Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9P126
UPID:
CLC1B_HUMAN
Alternative names:
C-type lectin-like receptor 2
Alternative UPACC:
Q9P126; Q6UWX7; Q8NHR6
Background:
C-type lectin domain family 1 member B, alternatively known as C-type lectin-like receptor 2, plays a pivotal role in platelet activation through its interaction with PDPN. This interaction triggers a cascade involving SRC and SYK tyrosine kinases, culminating in PLCG2 activation. Additionally, it serves as a receptor for rhodocytin from snake venom and HIV-1, facilitating platelet aggregation and virus capture, respectively.
Therapeutic significance:
Understanding the role of C-type lectin domain family 1 member B could open doors to potential therapeutic strategies. Its involvement in platelet activation and pathogen interaction highlights its potential as a target for modulating immune responses and preventing pathogen spread.